CN105287812A - Medicine composition for treating irritable bowel syndromes and application of medicine composition - Google Patents
Medicine composition for treating irritable bowel syndromes and application of medicine composition Download PDFInfo
- Publication number
- CN105287812A CN105287812A CN201510413454.6A CN201510413454A CN105287812A CN 105287812 A CN105287812 A CN 105287812A CN 201510413454 A CN201510413454 A CN 201510413454A CN 105287812 A CN105287812 A CN 105287812A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- irritable bowel
- dosage form
- radix paeoniae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a medicine composition for treating irritable bowel syndromes. The medicine composition in a dosage form comprises, by weight, 6-13.5 parts of white peony roots, 3-9 parts of dried tangerine or orange peel and 3-9 parts of white atractylodes rhizome. The invention further provides another medicine composition for treating the irritable bowel syndromes. The other medicine composition in a dosage form comprises, by weight, 6-13.5 parts o white peony roots, 3-9 parts of dried tangerine or orange peel, 3-9 parts of white atractylodes rhizome and 1.5-4.5 parts of clove. The medicine compositions have the advantages that the medicine compositions are precise and appropriate in compatibility of prescription, accordingly, synergistic effects can be realized, the irritable bowel syndromes can be effectively treated, and novel options can be provided for clinical medication.
Description
Technical field
The present invention relates to a kind of medical composition and its use for the treatment of irritable bowel syndrome.
Background technology
Irritable bowel syndrome (IBS) is one group to be continued or interval outbreak, and to suffer from abdominal pain, abdominal distention, bowl evacuation habit and (or) stool change into clinical manifestation, and lack the function of intestinal canal disorder disease of gastrointestinal tract structure and biochemistry exception.Classical symptom is stomachache, the abdominal distention relevant to abnormal defecation, is divided into according to cardinal symptom: diarrhea predominance type; Constipation leading type; Alternating diarrhea and constipation type.The factors such as spirit, diet, cold can be lured symptom recurrence into or be increased the weight of.
Current Chinese medicine is treatment irritable bowel syndrome is common methods.As Chinese patent application: CN103705891A, disclose a kind of Chinese medicine preparation for the treatment of diarrhea type irritable bowel syndrome, select Semen Lablab Album, Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, Poria, the Radix Paeoniae Alba, Radix Saposhnikoviae, Rhizoma Dioscoreae, Pericarpium Citri Reticulatae, Rhizoma Zingiberis Preparatum, Cortex Cinnamomi to combine.Chinese patent application: 103463417A, disclose a kind of Chinese medicine for the treatment of irritable bowel syndrome, it is the medicament be made up according to a conventional method of following raw materials according medicine: Radix Codonopsis, the Radix Astragali, the Rhizoma Atractylodis Macrocephalae, Poria, Rhizoma Dioscoreae, Radix Bupleuri, Radix Paeoniae Alba (parched), Radix Glycyrrhizae Preparata, Rhizoma Corydalis, Semen Lablab Album, the Radix Linderae, Pericarpium Citri Reticulatae.
Summary of the invention
The object of the present invention is to provide a kind of medical composition and its use for the treatment of irritable bowel syndrome.
Present invention also offers a kind of pharmaceutical composition for the treatment of irritable bowel syndrome, it is the dosage form be prepared from by the crude drug of following weight proportion:
The Radix Paeoniae Alba 6 ~ 13.5 parts, Pericarpium Citri Reticulatae 3 ~ 9 parts, the Rhizoma Atractylodis Macrocephalae 3 ~ 9 parts.
Further, it is the dosage form be prepared from by the crude drug of following weight proportion:
The Radix Paeoniae Alba 9 parts, Pericarpium Citri Reticulatae 6 parts, the Rhizoma Atractylodis Macrocephalae 6 parts.
Present invention also offers a kind of pharmaceutical composition for the treatment of irritable bowel syndrome, it is the dosage form be prepared from containing, for example the crude drug of lower weight proportion:
The Radix Paeoniae Alba 6 ~ 13.5 parts, Pericarpium Citri Reticulatae 3 ~ 9 parts, the Rhizoma Atractylodis Macrocephalae 3 ~ 9 parts, Flos Caryophylli 1.5 ~ 4.5 parts.
Further, it is the dosage form be prepared from containing, for example the crude drug of lower weight proportion:
The Radix Paeoniae Alba 9 parts, Pericarpium Citri Reticulatae 6 parts, the Rhizoma Atractylodis Macrocephalae 6 parts, Flos Caryophylli 3 parts.
Further, described crude drug also comprises Cortex Phellodendri.
Further, the consumption of Cortex Phellodendri is 3 ~ 9 weight portions.
Preferably, the consumption of Cortex Phellodendri is 6 weight portions.
Wherein, it be by the medicated powder of crude drug, water extract, ethanol extraction or/and other solvent extracts are active component, add the dosage form that pharmaceutically conventional adjuvant or complementary composition are prepared from.
Other solvent extracts described, as carbon dioxide supercritical fluid extraction thing.
Water extract or be used as medicine with medicated powder is all Chinese medicine tradition occupation modes, and after water extraction, because the soluble end of water is wide, can, by most of effective ingredient stripping, medicine is more easily absorbed by the body, onset be faster, the form of medication such as such as decoction; Be used as medicine with former powder, the surface area of medicated powder is larger, also effective ingredient absorption in vivo in medical material is conducive to, but medical material un-extracted, effective ingredient still needs stripping in vivo to absorb again, and the relative water extract of its onset is comparatively slow, but also weakens the toxicity that in medical material, harmful components cause human body simultaneously, be suitable for long-term taking, as former powder is prepared into the form of medication such as pill.At present in pharmacy procedure, ethanol extracts medicine as solvent, also be one of the most common extracting mode, ethanol is semi-polarity solvent, solubility property circle is between polarity and non-polar solven, some composition water miscible can be dissolved, also some compositions that non-polar solven dissolves can be dissolved, usually decocting is replaced with ethanol extraction, thus avoid the stripping of a large amount of invalid components, improve concentration and the extraction efficiency of effective ingredient, but comparatively water is expensive for the price of ethanol, in the large production of modern pharmaceutical industry, in order to save production cost, usually still based on decocting.When known compositions water extract of the present invention has physiologically active, demand during in order to adapt to various production and use, optionally water extraction, former powder, alcohol extraction or their compound mode can prepare concrete dosage form.
Water extract described in the present invention or ethanol extraction, comprise the various extracting modes such as decoction, backflow, warm macerating, ultrasonic, normal pressure or decompression extraction, as long as with water or ethanol for solvent, be aided with conventional sense means, all can reach same or analogous extraction effect.
Pharmaceutically acceptable adjuvant of the present invention includes but are not limited to filler (diluent), lubricant (fluidizer or antitack agent), dispersant, wetting agent, binding agent, regulator, solubilizing agent, antioxidant, antibacterial, emulsifying agent, disintegrating agent etc.Binding agent comprises syrup, arabic gum, gelatin, sorbitol, tragacanth, cellulose and its derivates (as microcrystalline Cellulose, sodium carboxymethyl cellulose, ethyl cellulose or hydroxypropyl methylcellulose etc.), gelatine size, syrup, starch slurry or polyvinylpyrrolidone etc.; Filler comprises lactose, Icing Sugar, dextrin, starch and derivant thereof, cellulose and its derivates, inorganic calcium salt (as calcium sulfate, calcium phosphate, calcium hydrogen phosphate, precipitated calcium carbonate etc.), sorbitol or glycine etc.; Lubricant comprises micropowder silica gel, magnesium stearate, Pulvis Talci, aluminium hydroxide, boric acid, hydrogenated vegetable oil, Polyethylene Glycol etc.; Disintegrating agent comprises starch and derivant (as carboxymethyl starch sodium, Explotab, pregelatinized Starch, modified starch, hydroxypropyl starch, corn starch etc.), polyvinylpyrrolidone or microcrystalline Cellulose etc.; Wetting agent comprises sodium lauryl sulphate, water or alcohol etc.; Antioxidant packages is containing sodium sulfite, sodium sulfite, sodium pyrosulfite, dibutyl benzoic acid etc.; Antibacterial comprises 0.5% phenol, 0.3% cresol, 0.5% chlorobutanol etc.; Regulator comprises hydrochloric acid, citric acid, potassium hydroxide (sodium), sodium citrate and buffer agent (comprising phosphoric acid dioxy sodium and sodium hydrogen phosphate) etc.; Emulsifier package containing Tween-80, do not have that sour Pyrusussuriensis is smooth, pluronic gram F-68, lecithin, fabaceous lecithin etc.; Solubilizing agent comprises tween 80, bile, glycerol etc.
Described pharmaceutically acceptable complementary composition, it has certain physiologically active, but adding of this composition can not change the leading position of aforementioned pharmaceutical compositions in treatment of diseases, and only play auxiliary effect, certain active summation action (not Synergistic) can be produced after it and aforementioned pharmaceutical compositions conbined usage, and these auxiliary effects are only the utilizations to this composition known activity, it is the usual adjuvant treatment modality of field of medicaments.If by above-mentioned complementary composition and pharmaceutical composition of the present invention with the use of, still should belong to the scope of protection of the invention.
Further, described dosage form is through gastrointestinal absorption dosage form or percutaneous absorption type.Such as, through gastrointestinal absorption dosage form can be pill, tablet, powder, capsule, granule, oral liquid.
Present invention also offers the purposes of aforementioned pharmaceutical compositions in the medicine of preparation treatment irritable bowel syndrome.
Further, described irritable bowel syndrome is diarrhea type irritable bowel syndrome.
Present invention also offers the preparation method of the above-mentioned pharmaceutical composition containing Cortex Phellodendri, it comprises following operating procedure:
(1) get Pericarpium Citri Reticulatae, Flos Caryophylli, extraction by steam distillation volatile oil, use betacyclodextrin enclose, for subsequent use, distillate is for subsequent use; Medicinal residues extracting in water, merge extractive liquid, is concentrated into clear paste A;
(2) get the Radix Paeoniae Alba, the Rhizoma Atractylodis Macrocephalae, Cortex Phellodendri, with ethanol extraction, merge alcohol extract, be concentrated into the clear paste B without alcohol taste;
(3) distillate, clear paste A, clear paste B are merged preparation, to obtain final product.
Further, in step (1), medicinal residues decoct with water extraction.
Further, extraction 2 times is decocted, each 1 ~ 3 hour.
Further, in step (2), the concentration of ethanol is 40 ~ 95%, is preferably 50 ~ 70%, more elects 60% as.
Further, ethanol extraction adopts reflux type.
Further, alcohol reflux 2 times, each 1 ~ 4 hour, is preferably 3 hours.
Pharmaceutical composition of the present invention, prescription compatibility of medicines is precise and appropriate, creates synergistic function, effectively can treat irritable bowel syndrome, for clinical application provides new selection.
Detailed description of the invention
Embodiment 1: the preparation of capsule
Radix Paeoniae Alba Pericarpium Citri Reticulatae Rhizoma Atractylodis Macrocephalae Flos Caryophylli Cortex Phellodendri;
First Pericarpium Citri Reticulatae, Flos Caryophylli are added 8 times of water gagings and distill 5 hours, collect volatile oil for subsequent use, distillate and aqueous solution merging are concentrated into dry cream; The Radix Paeoniae Alba, the Rhizoma Atractylodis Macrocephalae, Cortex Phellodendri 3 taste are with 8 times amount 60% alcohol reflux 2 times, and each 3 hours, backflow merged and reclaims ethanol, concentrated, is dried to the extractum of certain relative density.Dry cream is added extractum, conventionally makes capsule.
Embodiment 2: the preparation of soft capsule
Radix Paeoniae Alba Pericarpium Citri Reticulatae Rhizoma Atractylodis Macrocephalae Flos Caryophylli Cortex Phellodendri;
First Pericarpium Citri Reticulatae, Flos Caryophylli are added 8 times of water gagings and distill 5 hours, collect volatile oil for subsequent use, distillate and aqueous solution merging are concentrated into dry cream; The Radix Paeoniae Alba, the Rhizoma Atractylodis Macrocephalae, Cortex Phellodendri 3 taste are with 8 times amount 60% alcohol reflux 2 times, and each 3 hours, backflow merged and reclaims ethanol, concentrated, is dried to the extractum of certain relative density.Dry cream is added extractum, conventionally makes soft capsule.
Embodiment 3: the preparation of emplastrum
Radix Paeoniae Alba Pericarpium Citri Reticulatae Rhizoma Atractylodis Macrocephalae Flos Caryophylli Cortex Phellodendri;
First Pericarpium Citri Reticulatae, Flos Caryophylli are added 8 times of water gagings and distill 5 hours, collect volatile oil for subsequent use, distillate and aqueous solution merging are concentrated into dry cream; The Radix Paeoniae Alba, the Rhizoma Atractylodis Macrocephalae, Cortex Phellodendri 3 taste are with 8 times amount 60% alcohol reflux 2 times, and each 3 hours, backflow merged and reclaims ethanol, concentrated, is dried to the extractum of certain relative density.Dry cream is added extractum, conventionally makes emplastrum.
Embodiment 4: the preparation of injection
Radix Paeoniae Alba Pericarpium Citri Reticulatae Rhizoma Atractylodis Macrocephalae Flos Caryophylli Cortex Phellodendri;
First Pericarpium Citri Reticulatae, Flos Caryophylli are added 8 times of water gagings and distill 5 hours, collect volatile oil for subsequent use, distillate and aqueous solution merging are concentrated into dry cream; The Radix Paeoniae Alba, the Rhizoma Atractylodis Macrocephalae, Cortex Phellodendri 3 taste are with 8 times amount 60% alcohol reflux 2 times, and each 3 hours, backflow merged and reclaims ethanol, concentrated, is dried to the extractum of certain relative density.Dry cream is added extractum, after refining, conventionally makes injection.
Embodiment 5: the preparation of granule
Radix Paeoniae Alba Pericarpium Citri Reticulatae Rhizoma Atractylodis Macrocephalae Flos Caryophylli Cortex Phellodendri;
First Pericarpium Citri Reticulatae, Flos Caryophylli are added 8 times of water gagings and distill 5 hours, collect volatile oil for subsequent use, distillate and aqueous solution merging are concentrated into dry cream; The Radix Paeoniae Alba, the Rhizoma Atractylodis Macrocephalae, Cortex Phellodendri 3 taste are with 8 times amount 60% alcohol reflux 2 times, and each 3 hours, backflow merged and reclaims ethanol, concentrated, is dried to the extractum of certain relative density.Dry cream is added extractum, conventionally makes granule.
Embodiment 6: the preparation of tablet
Radix Paeoniae Alba Pericarpium Citri Reticulatae Rhizoma Atractylodis Macrocephalae Flos Caryophylli Cortex Phellodendri;
First Pericarpium Citri Reticulatae, Flos Caryophylli are added 8 times of water gagings and distill 5 hours, collect volatile oil for subsequent use, distillate and aqueous solution merging are concentrated into dry cream; The Radix Paeoniae Alba, the Rhizoma Atractylodis Macrocephalae, Cortex Phellodendri 3 taste are with 8 times amount 60% alcohol reflux 2 times, and each 3 hours, backflow merged and reclaims ethanol, concentrated, is dried to the extractum of certain relative density.Dry cream is added extractum, conventionally makes tablet.
Embodiment 7: the preparation of mixture (oral liquid)
Radix Paeoniae Alba Pericarpium Citri Reticulatae Rhizoma Atractylodis Macrocephalae Flos Caryophylli Cortex Phellodendri;
First Pericarpium Citri Reticulatae, Flos Caryophylli are added 8 times of water gagings and distill 5 hours, collect volatile oil for subsequent use, distillate and aqueous solution merge the extractum being concentrated into certain density; The Radix Paeoniae Alba, the Rhizoma Atractylodis Macrocephalae, Cortex Phellodendri 3 taste are with 8 times amount 60% alcohol reflux 2 times, and each 3 hours, backflow merged and reclaims ethanol, concentrated, is dried to the extractum of certain relative density.Refining after merging extractum, conventionally make mixture (oral liquid).
The present invention is side entirely: Radix Paeoniae Alba 9g, Pericarpium Citri Reticulatae 6g, Rhizoma Atractylodis Macrocephalae 6g, Flos Caryophylli 3g, Cortex Phellodendri 6g, each administration 7.5 ~ 15g crude drug, 2 times on the one.
Beneficial effect of the present invention is illustrated below by way of test example
Test example 1
One, animal:
SPF level SD rat, body weight 180-220g, female.Be purchased from Chinese medicine study institute Experimental Animal Center, for testing after experimental rat balance raises 3d.
Two, modeling method:
Get 140 rats, make D-IBS rat model with the constraint of breast milk separation+acetic acid stimulation+extremity.
Three, divide into groups:
After modeling success, be grouped into according to prescription: Normal group, model control group, Western medicine positive group, tongxieyao formula square foundation high dose group, tongxieyao formula square foundation low dose group, square foundation high dose group of the present invention, square foundation low dose group of the present invention, square foundation of the present invention adds Flos Caryophylli high dose group, square foundation of the present invention adds Flos Caryophylli low dose group, the present invention full side high dose group, the present invention full side low dose group, tongxieyao formula full side high dose group, the full side's low dose group of tongxieyao formula, often organize 10 animals, amount to 13 groups.Every day gastric infusion once, continuous 14 days.
Wherein, the prescription proportioning of square foundation of the present invention is: Radix Paeoniae Alba 9g, Rhizoma Atractylodis Macrocephalae 6g, Pericarpium Citri Reticulatae 6g;
The prescription proportioning that square foundation of the present invention adds Flos Caryophylli group is: Radix Paeoniae Alba 9g, Pericarpium Citri Reticulatae 6g, Rhizoma Atractylodis Macrocephalae 6g, Flos Caryophylli 3g;
The prescription proportioning of the full side of the present invention is: Radix Paeoniae Alba 9g, Pericarpium Citri Reticulatae 6g, Rhizoma Atractylodis Macrocephalae 6g, Flos Caryophylli 3g, Cortex Phellodendri 6g;
Tongxieyao formula square foundation prescription proportioning is: Rhizoma Atractylodis Macrocephalae 9g, Radix Paeoniae Alba 6g, Pericarpium Citri Reticulatae 4.5g;
Tongxieyao formula full side's prescription proportioning is: Rhizoma Atractylodis Macrocephalae 9g, Radix Paeoniae Alba 6g, Pericarpium Citri Reticulatae 4.5g, Radix Saposhnikoviae 6g.
2 dosage groups are all selected in the present invention's experiment, and carry out administration by crude drug amount, high dose is 8g crude drug/kg, and low dosage is 2g crude drug/kg.Material used is prepared by the following method:
First Pericarpium Citri Reticulatae, Flos Caryophylli are added 8 times of water gagings and distill 5 hours, collect volatile oil, use betacyclodextrin enclose, for subsequent use, retain distillate, medicinal residues decoct with water 2 times, each 1 hour, and 2 decoction liquor and distillate merge, and are concentrated into clear paste; The Radix Paeoniae Alba, the Rhizoma Atractylodis Macrocephalae, Cortex Phellodendri 3 taste are with 8 times amount 60% alcohol reflux 2 times, and each 3 hours, backflow merged and reclaims ethanol, is concentrated into the clear paste without alcohol taste, is dried to the extractum of certain relative density.
Four, Indexs measure:
1, carry out feces after the administration is complete to count and intestinal sensitivity assessment.2, eye socket blood is got according to test kit requirement operation, Analyze 5-HT and the element-8 that is carefully situated between in vain.3, experiment terminates rear rat sacrificed by decapitation, gets the coton and rectal in distance anus 8cm, sucks blood after taking out living tissue, weigh, add the grinding of 1ml normal saline as early as possible, make homogenate, leave the heart 15 minutes for 4 degree, 3000, get supernatant-80 and preserve, Analyze 5-HT and the element-8 that is carefully situated between in vain.
Five, result of the test
1, the investigation of square foundation compatibility
(1) Preliminary screening chooses key index, investigates the proportioning of the Radix Paeoniae Alba, Pericarpium Citri Reticulatae, the Rhizoma Atractylodis Macrocephalae, according to the drug dose that Chinese medicine is conventional, carry out proportions, each test different dosing group crude drug dosage used is consistent, and high dose is 8g crude drug/kg, and low dosage is 2g crude drug/kg.The results are shown in Table 1:
Above result display, the alone Radix Paeoniae Alba, Pericarpium Citri Reticulatae and the Rhizoma Atractylodis Macrocephalae have certain effect, but not as good as share effect, alone three groups, Radix Paeoniae Alba effect is best.
(2) be the optimal proportion of screening three taste main Chinese medicinal materials further, according to the drug dose that Chinese medicine is conventional, carry out proportions, unanimously, high dose is 8g crude drug/kg to each test different dosing group crude drug dosage used, and low dosage is 2g crude drug/kg.The results are shown in Table 2:
Above result display, three taste medical material compatibilities are with the Radix Paeoniae Alba: Pericarpium Citri Reticulatae: the Rhizoma Atractylodis Macrocephalae=3:2:2 effect is best.
2, square foundation of the present invention and tongxieyao formula square foundation comparative result are in table 3
Table 3 square foundation of the present invention and tongxieyao formula square foundation comparative result table
Note: respectively organize and compare * p < 0.05, * * p < 0.01, * * * p < 0.001. with model group
The blank group of experimental result display statistically all has pole significant difference with the more each observation index of model group, and prompting modeling is successful.Positive drug and each observation index of tongxieyao formula square foundation high dose statistically all have obviously or significant difference, and prompting is effective medicine both.Square foundation high dose group of the present invention and each observation index of low dose group statistically all have obviously or significant difference, and comparatively tongxieyao formula square foundation is in spasmolytic to point out square foundation drug effect of the present invention, and diarrhea, alleviates on IBS, be all better than the latter.
3, square foundation of the present invention and square foundation of the present invention add Flos Caryophylli group comparative result in table 4
Table 4 square foundation of the present invention and square foundation of the present invention add Flos Caryophylli group comparative result table
Note: respectively organize and compare * p < 0.05, * * p < 0.01, * * * p < 0.001. with model group
The blank group of experimental result display statistically all has pole significant difference with the more each observation index of model group, and prompting modeling is successful.The each observation index of positive drug statistically all has obviously or difference, and prompting positive drug is effective medicine.Although the Flos Caryophylli high low dose group that adds square foundation of the present invention does not compare with square foundation height dosage component of the present invention do not have significant difference, but square foundation of the present invention adds the drug effect of Flos Caryophylli high low dose group more obviously viewed from the result that respective and model group compare, it is necessary that prompting Flos Caryophylli exists in prescription.
4, square foundation of the present invention adds Flos Caryophylli group and the present invention and entirely just compares and the results are shown in Table 5
Table 5 square foundation of the present invention adds Flos Caryophylli group and the present invention just compares result table entirely
Note: respectively organize and compare * p < 0.05 with model group, * p < 0.01, * * p < 0.001, square foundation of the present invention adds Flos Caryophylli and adds Cortex Phellodendri high and low dose group and add Flos Caryophylli high and low dose group respectively with square foundation of the present invention and compare △ p < 0.05, △ △ p < 0.01.
The blank group of experimental result display statistically all has pole significant difference with the more each observation index of model group, and prompting modeling is successful.The each observation index of positive drug statistically all has obviously or difference, and prompting positive drug is effective medicine.The Flos Caryophylli high dose group that adds the present invention's full side high dose group and square foundation of the present invention compares and has obviously or significant difference, points out square foundation of the present invention to add Flos Caryophylli and adds Cortex Phellodendri high dose group to add Flos Caryophylli high dose group drug effect than the present invention square foundation more obvious.Illustrate that adding of Cortex Phellodendri creates synergistic function, significantly improve drug activity.
5, the full side of the present invention and tongxieyao formula comparative result are in table 6
The full side of table 6 the present invention and tongxieyao formula comparison sheet
Note: administration group compares * p < 0.05 with model group, * p < 0.01, * * p < 0.001, square foundation of the present invention add Flos Caryophylli add Cortex Phellodendri high and low dose group respectively side high and low dose group complete in tongxieyao formula compare △ p < 0.05.
The blank group of experimental result display statistically all has pole significant difference with the more each observation index of model group, and prompting modeling is successful.The each observation index of positive drug statistically all has obviously or difference, and prompting positive drug is effective medicine.The full side's high dose group of the present invention and tongxieyao formula compare and have notable difference, and the full side of prompting the present invention is more obvious than tongxieyao formula full presciption medicine effect.
Claims (17)
1. treat a pharmaceutical composition for irritable bowel syndrome, it is characterized in that: it is the dosage form be prepared from by the crude drug of following weight proportion:
The Radix Paeoniae Alba 6 ~ 13.5 parts, Pericarpium Citri Reticulatae 3 ~ 9 parts, the Rhizoma Atractylodis Macrocephalae 3 ~ 9 parts.
2. pharmaceutical composition according to claim 1, is characterized in that: it is the dosage form be prepared from by the crude drug of following weight proportion:
The Radix Paeoniae Alba 9 parts, Pericarpium Citri Reticulatae 6 parts, the Rhizoma Atractylodis Macrocephalae 6 parts.
3. treat a pharmaceutical composition for irritable bowel syndrome, it is characterized in that: it is the dosage form be prepared from containing, for example the crude drug of lower weight proportion:
The Radix Paeoniae Alba 6 ~ 13.5 parts, Pericarpium Citri Reticulatae 3 ~ 9 parts, the Rhizoma Atractylodis Macrocephalae 3 ~ 9 parts, Flos Caryophylli 1.5 ~ 4.5 parts.
4. pharmaceutical composition according to claim 3, is characterized in that: it is the dosage form be prepared from containing, for example the crude drug of lower weight proportion:
The Radix Paeoniae Alba 9 parts, Pericarpium Citri Reticulatae 6 parts, the Rhizoma Atractylodis Macrocephalae 6 parts, Flos Caryophylli 3 parts.
5. pharmaceutical composition according to claim 3, is characterized in that: described crude drug also comprises Cortex Phellodendri.
6. pharmaceutical composition according to claim 5, is characterized in that: the consumption of Cortex Phellodendri is 3 ~ 9 weight portions.
7. pharmaceutical composition according to claim 6, is characterized in that: the consumption of Cortex Phellodendri is 6 weight portions.
8. the pharmaceutical composition according to claim 1 ~ 7 any one, it is characterized in that: it be by the medicated powder of crude drug, water extract, ethanol extraction or/and other solvent extracts are active component, add the dosage form that pharmaceutically conventional adjuvant or complementary composition are prepared from.
9. the pharmaceutical composition according to claim 1 ~ 8 any one, is characterized in that: described dosage form is through gastrointestinal absorption dosage form or percutaneous absorption type.
10. the purposes of pharmaceutical composition described in claim 1 ~ 9 any one in the medicine of preparation treatment irritable bowel syndrome.
11. purposes according to claim 10, is characterized in that: described irritable bowel syndrome is diarrhea type irritable bowel syndrome.
The preparation method of pharmaceutical composition described in 12. claim 5 ~ 7 any one, is characterized in that: it comprises following operating procedure:
(1) get Pericarpium Citri Reticulatae, Flos Caryophylli, extraction by steam distillation volatile oil, use betacyclodextrin enclose, for subsequent use, distillate is for subsequent use; Medicinal residues extracting in water, merge extractive liquid, is concentrated into clear paste A;
(2) get the Radix Paeoniae Alba, the Rhizoma Atractylodis Macrocephalae, Cortex Phellodendri, with ethanol extraction, merge alcohol extract, be concentrated into the clear paste B without alcohol taste;
(3) distillate, clear paste A, clear paste B are merged preparation, to obtain final product.
13. preparation methoies according to claim 12, is characterized in that: in step (1), medicinal residues decoct with water extraction.
14. preparation methoies according to claim 13, is characterized in that: decoct extraction 2 times, each 1 ~ 3 hour.
15. preparation methoies according to claim 12, is characterized in that: in step (2), and the concentration of ethanol is 40 ~ 95%, are preferably 50 ~ 70%, more elect 60% as.
16. preparation methoies according to claim 12 or 15, is characterized in that: ethanol extraction adopts reflux type.
17. preparation methoies according to claim 16, is characterized in that: alcohol reflux 2 times, each 1 ~ 4 hour, are preferably 3 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510413454.6A CN105287812B (en) | 2014-07-16 | 2015-07-14 | A kind of medical composition and its use for treating irritable bowel syndrome |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410338938 | 2014-07-16 | ||
| CN2014103389384 | 2014-07-16 | ||
| CN201510413454.6A CN105287812B (en) | 2014-07-16 | 2015-07-14 | A kind of medical composition and its use for treating irritable bowel syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105287812A true CN105287812A (en) | 2016-02-03 |
| CN105287812B CN105287812B (en) | 2019-07-02 |
Family
ID=55186099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510413454.6A Active CN105287812B (en) | 2014-07-16 | 2015-07-14 | A kind of medical composition and its use for treating irritable bowel syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105287812B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105796654A (en) * | 2016-04-05 | 2016-07-27 | 中国人民武装警察部队后勤学院 | Traditional Chinese medicine composition for treating diarrhea irritable bowel syndrome, navel paste and application |
| CN108721417A (en) * | 2018-04-19 | 2018-11-02 | 广东联鲲集团有限公司 | A kind of additive and its preparation method and application for preventing hito enteritis |
| CN108785633A (en) * | 2018-08-03 | 2018-11-13 | 玉林市中医医院 | A kind of Chinese medicine composition and its preparation for treating chronic diarrhea |
| CN111346193A (en) * | 2019-08-12 | 2020-06-30 | 首都医科大学附属北京中医医院 | Pharmaceutical composition for preventing and/or treating diarrhea-predominant irritable bowel syndrome, and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101224287A (en) * | 2007-12-27 | 2008-07-23 | 佟家勇 | Oral administration Chinese traditional medicine for treating acne and preparing method thereof |
-
2015
- 2015-07-14 CN CN201510413454.6A patent/CN105287812B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101224287A (en) * | 2007-12-27 | 2008-07-23 | 佟家勇 | Oral administration Chinese traditional medicine for treating acne and preparing method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 王付: "《方剂学临床应用要旨》", 31 August 2013, 人民军医出版社 * |
| 胡旭光等: "痛泻要方是否配伍防风治疗肝郁脾虚腹泻型肠易激综合征35例临床观察", 《新中医》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105796654A (en) * | 2016-04-05 | 2016-07-27 | 中国人民武装警察部队后勤学院 | Traditional Chinese medicine composition for treating diarrhea irritable bowel syndrome, navel paste and application |
| CN105796654B (en) * | 2016-04-05 | 2020-07-03 | 中国人民武装警察部队后勤学院 | Traditional Chinese medicine composition for treating diarrhea-predominant irritable bowel syndrome, navel patch and application |
| CN108721417A (en) * | 2018-04-19 | 2018-11-02 | 广东联鲲集团有限公司 | A kind of additive and its preparation method and application for preventing hito enteritis |
| CN108785633A (en) * | 2018-08-03 | 2018-11-13 | 玉林市中医医院 | A kind of Chinese medicine composition and its preparation for treating chronic diarrhea |
| CN111346193A (en) * | 2019-08-12 | 2020-06-30 | 首都医科大学附属北京中医医院 | Pharmaceutical composition for preventing and/or treating diarrhea-predominant irritable bowel syndrome, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105287812B (en) | 2019-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103990081A (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating infant jaundice | |
| CN104338062A (en) | Chinese medicinal preparation for treating stomachache and diarrhea | |
| CN103520293B (en) | Improve and treat the Chinese medicine for oral administration of constipation | |
| CN103784933A (en) | Recurrent oral ulcer power | |
| CN105287812A (en) | Medicine composition for treating irritable bowel syndromes and application of medicine composition | |
| CN101607074A (en) | A kind of drug regimen for the treatment of chronic gastritis and preparation method thereof | |
| CN104825788A (en) | Application of traditional Chinese medicine composition in preparation of drug for treating transient ischemic attack | |
| CN104000944B (en) | A kind of health products or pharmaceutical composition and its production and use with warming kidney to invigorate yang | |
| CN102552520B (en) | Blood circulation-promoting and pain-stopping medicament and preparation process and application thereof | |
| CN102188522B (en) | Traditional Chinese medicine composition for treating constipation | |
| CN104491459A (en) | Traditional Chinese medicine composition for treating tumors | |
| CN104324316A (en) | Application of traditional Chinese medicine composition to prepare medicines treating colorectal cancer | |
| CN101254266B (en) | Cardiac and cerebral vascular disease treating medicine | |
| CN1943755B (en) | A Chinese traditional medicinal composition for treatment of hypertension and its preparation method | |
| CN103041233A (en) | Pharmaceutical composition for treating infantile diarrhea and preparation method thereof | |
| CN107213197A (en) | A kind of Chinese medicine composition and its application in prevention or treatment hypertension drug is prepared | |
| CN108143875B (en) | Traditional Chinese medicine composition for treating diabetic gastroparesis and preparation method thereof | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN104983759A (en) | Traditional Chinese medicine composition treating diabetic nephropathy and preparing method thereof | |
| CN104784650A (en) | Pharmaceutical preparation for clinical nursing of gastric ulcer | |
| CN103920023A (en) | Traditional Chinese medicine for treating hypertension | |
| CN103432502B (en) | A kind of Chinese patent medicine for the treatment of peptic ulcer disease | |
| CN103191243A (en) | Application of medicament composition composed of coptis chinensis and fructus evodiae and preparation method of medicament composition | |
| CN106581468A (en) | Preparation method of traditional Chinese medicine capable of treating gastric ulcer | |
| CN102688254B (en) | Medicinal composition for treating chronic diarrhea and preparation method and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210107 Address after: No. 709, 7th floor, unit 2, building 1, No. 1700, North Tianfu Avenue, high tech Zone, Chengdu, Sichuan 610000 Patentee after: CHENGDU SAINUO LIANCHUANG BIOLOGY TECHNOLOGY Co.,Ltd. Address before: 611130 room 1201, unit 1, building 1, No. 268, Laifeng Road, Wenjiang District, Chengdu City, Sichuan Province Patentee before: CHENGDU SANHENG HECHUANG BIOTECHNOLOGY Co.,Ltd. |